Decision on access to new blood cancer drug

 NHS patients in England and Wales with chronic lymphocytic leukaemia (CLL) could soon benefit from Gazyvaro.

Gazyvaro, which has today been given the provisional green light by the National Institute for Health and Care Excellence (NICE). Gazyvaro is the first 'type II' anti-CD20 monoclonal antibody licensed for the treatment of CLL designed to attack blood cancers more aggressively than 'type I' treatments.

Original source


Register for receiving PharmaAround news, register for PharmAround events.
Continue registration